A phase 1 study evaluated whether the use of alpha1-antitrypsin, an approved medication for patients with congenital deficiency of alpha-1 antitrypsin associated with emphysema, is beneficial in acute attacks of NMO, improving patient disability and quality of life (NCT02087813). This evidence concerns the gene SERPINA1 and pulmonary emphysema.